A prospective study of dextran-induced anaphylactoid reactions in 5745 patients.
A prospective study of dextran-induced anaphylactoid reactions (DIAR) in 5745 gynaecological and obstetric patients who received dextran 70 solution intravenously while undergoing major surgery revealed 8 patients who had Grade I or II reactions and 7 patients who had Grade III or IV reactions. The incidence of severe reactions was 1:821 patients treated. The overall incidence of reactions per patient treated was 1:383. One neonatal death followed a dextran-induced cardiac arrest in a woman about to undergo caesarean section. The risks of dextran 70 treatment exceeded the risks of thromboembolism in these patients.
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D000773:Anesthesia, Obstetrical; D002585:Cesarean Section; D003911:Dextrans / Q000009:adverse effects*; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D010952:Plasma Substitutes / Q000009:adverse effects*; D011247:Pregnancy; D011446:Prospective Studies
D003911:Dextrans; D010952:Plasma Substitutes